en
svPress releases
Regulatory press release 2024-02-14
Interim Report Fourth Quarter 2023
Regulatory press release 2024-02-12
FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July
Regulatory press release 2024-02-07
Xspray Pharma appoints Michael af Winklerfelt as acting CFO
Regulatory press release 2023-12-29
New number of shares and votes in Xspray Pharma
Regulatory press release 2023-12-01
Xspray Pharma raises SEK 92.3 million through warrants TO5
Press release 2023-11-21
Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage
Press release 2023-11-16
Important information to holders of warrants series TO5: The subscription period is ongoing
Regulatory press release 2023-11-09
Xspray Pharma’s large shareholders and key individuals declare their intent to exercise TO5 warrants in November
Regulatory press release 2023-11-08
Interim Report Third Quarter 2023
Press release 2023-10-26